Comparison of speed and effectiveness of reversal agent(sugammadex) at two different doses for reversal of vecuronium induced neuromuscular block during elective surgery

Comparison of Sugammadex at Two different doses for Reversal of Vecuronium Induced Neuromuscular Block-A Randomized Prospective Study Design - Nil

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/11/097912

Enrollment

Registered

2025-11-24

Start date

Unknown

Completion date

Unknown

Last updated

2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: Giving reversal agent sugammadex at 2mg/Kg(intravenously ). Patients will receive only one dose at the end of surgery: Giving reversal agent sugammadex at 4mg/Kg (intavenously).Patients

Eligibility

Inclusion criteria

Inclusion criteria: ASA 1 and 2 patients scheduled to undergo elective surgery under vecuronium induced neuro muscular block

Exclusion criteria

Exclusion criteria: neuromuscular disorders,allergy to study drug and vecuronium

Design outcomes

Primary

Measure	Time frame
Time to acchieve TOF(Train of Four) ratio of 0.9Timepoint: At extubation ,after giving reversal agents , patients will be monitored by TOF monitor(Every 10sec)	—

Secondary

Measure	Time frame
Episodes of incomplete reversal Recurrent neuromuscularblockade Post op respiratory complicationsTimepoint: Patients will be monitored every 30mins till 6hrs after extubation	—

Countries

India

Contacts

Public ContactN V Vinoth Kumar

JSS Medical college and hospital

vinojipmer1982@gmail.com8870461581

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026